2023
Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF
Vaduganathan M, Mentz R, Claggett B, Miao Z, Kulac I, Ward J, Hernandez A, Morrow D, Starling R, Velazquez E, Williamson K, Desai A, Zieroth S, Lefkowitz M, McMurray J, Braunwald E, Solomon S. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. European Heart Journal 2023, 44: 2982-2993. PMID: 37210743, PMCID: PMC10424880, DOI: 10.1093/eurheartj/ehad344.Peer-Reviewed Original ResearchConceptsSacubitril/valsartanRenal composite endpointPARAGON-HFHeart failureEjection fractionPooled analysisHF eventsRenal eventsCardiovascular deathComposite endpointLeft ventricular ejection fractionVentricular ejection fractionActive-controlled trialParticipant-level dataPrimary endpointSecondary endpointsClinical outcomesNatriuretic peptideLike patientsTreatment benefitCare settingsPatientsPrimary analysisLVEFValsartanRationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event
Mentz R, Ward J, Hernandez A, Lepage S, Morrow D, Sarwat S, Sharma K, Solomon S, Starling R, Velazquez E, Williamson K, Zieroth S, Braunwald E. Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event. Journal Of Cardiac Failure 2023, 29: 922-930. PMID: 36796671, DOI: 10.1016/j.cardfail.2023.02.001.Peer-Reviewed Original ResearchConceptsSac/ValSacubitril/valsartanHeart failure eventsPARAGON-HF trialWHF eventNT-proBNPEjection fractionHeart failureClinical outcomesAmino-terminal pro-B-type natriuretic peptide levelsTerminal pro-B-type natriuretic peptide levelsB-type natriuretic peptide levelsDe novo HFChronic heart failureNatriuretic peptide levelsPrimary efficacy endpointPg/mLEfficacy endpointSafety endpointSecondary endpointsSymptomatic hypotensionBaseline characteristicsRenal functionStable patientsBlack patients
2020
Efficacy of Tafamidis in Transthyretin Amyloid Cardiomyopathy in the ATTR-ACT Trial
Berk J, Damy T, Drachman B, Elliott P, Gottlieb S, Grogan M, Gundapaneni B, Hanna M, Hoffman J, Hummel S, Judge D, Lenihan D, Merlini G, Patterson T, Rapezzi C, Schwartz J, Shah S, Sultan M, Velazquez E, Cruz M, Witteles R. Efficacy of Tafamidis in Transthyretin Amyloid Cardiomyopathy in the ATTR-ACT Trial. Heart & Lung 2020, 49: 209-210. DOI: 10.1016/j.hrtlng.2020.02.009.Peer-Reviewed Original ResearchEfficacy of tafamidisSix-minute walk distanceATTR-CMCause mortalityQuality of lifeWalk distanceHeart failureKansas City Cardiomyopathy Questionnaire overall scorePre-specified sensitivity analysisSix-minute walk test distanceTransthyretin Cardiomyopathy Clinical TrialHard cardiovascular endpointsFirst-line therapyKey secondary endpointPrimary efficacy analysisTransthyretin amyloid cardiomyopathyOverall scoreMechanical assist devicesClinical laboratory testsNovel study designNYHA classTafamidis groupPlacebo groupSecondary endpointsAdverse events
2013
Prediction of All-Cause Mortality and Heart Failure Admissions From Global Left Ventricular Longitudinal Strain in Patients With Acute Myocardial Infarction and Preserved Left Ventricular Ejection Fraction
Ersbøll M, Valeur N, Mogensen UM, Andersen MJ, Møller JE, Velazquez EJ, Hassager C, Søgaard P, Køber L. Prediction of All-Cause Mortality and Heart Failure Admissions From Global Left Ventricular Longitudinal Strain in Patients With Acute Myocardial Infarction and Preserved Left Ventricular Ejection Fraction. Journal Of The American College Of Cardiology 2013, 61: 2365-2373. PMID: 23563128, DOI: 10.1016/j.jacc.2013.02.061.Peer-Reviewed Original ResearchMeSH KeywordsAgedCause of DeathCohort StudiesConfidence IntervalsEchocardiography, DopplerFemaleHeart FailureHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPredictive Value of TestsPrognosisProportional Hazards ModelsProspective StudiesRisk AssessmentSeverity of Illness IndexStroke VolumeSurvival RateVentricular Dysfunction, LeftConceptsGlobal longitudinal strainHeart failure hospitalizationVentricular ejection fractionAcute myocardial infarctionMyocardial infarctionFailure hospitalizationSecondary endpointsEjection fractionHigh-risk myocardial infarctionVentricular global longitudinal strainLeft ventricular ejection fractionLongitudinal strainHeart failure admissionsPrimary composite endpointCox regression analysisHigh-risk subjectsVentricular longitudinal strainImportant prognostic informationSignificant prognostic valueAssessment of GLSParticular clinical relevanceCardiovascular deathCause mortalityPrimary endpointCardiac death